- The Weed Blog https://www.theweedblog.com

Marijuana An Effective Treatment For Neuropathic Pain, Says New Study


pain medical cannabis marijuanaCourtesy of The Joint Blog

A randomized, double-blind, placebo-controlled parallel group study published in this month’s issue of the European Journal of Pain, and published online early by the National Institute of Health, has found that cannabis can significantly reduce pain and improve sleep in those with neuropathic pain.

For the study; “303 patients with PNP (peripheral neuropathic pain) associated with allodynia were screened; 128 were randomized to THC/CBD spray and 118 to placebo, in addition to their current analgesic therapy.”

After conducting the study, which used a spray made from THC (tetrahydrocannabinol) and CBD (cannabidiol), both compounds of cannabis, researchers found that “a meaningful proportion of otherwise treatment-resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.”

The study, which was conducted by researchers a Gartnavel General Hospital at the University of Glasgow in the U.K., can be found by clicking here.

Source: TheJointBlog.Com


About Author

Johnny Green


  1. Do you deliver to,, Elephant Island Antarctica,,. We can’t grow shit down here. We have no phones, only a global radio. Can you be reached by radio ?
    61°08′S 55°07′W,, we will pay for postage.

  2. London, UK, January 14, 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of its previously announced follow-on offering on the NASDAQ Global Market of 2,441,110 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 366,165 additional ADSs at a price of $36.00 per ADS raising gross proceeds of $101.1 million…

Leave A Reply